HYUNDAI BIOLAND Co.Ltd
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines. It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients. The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDA… Read more
HYUNDAI BIOLAND Co.Ltd (052260) - Net Assets
Latest net assets as of September 2025: ₩137.95 Billion KRW
Based on the latest financial reports, HYUNDAI BIOLAND Co.Ltd (052260) has net assets worth ₩137.95 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩165.86 Billion) and total liabilities (₩27.91 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩137.95 Billion |
| % of Total Assets | 83.17% |
| Annual Growth Rate | 3.06% |
| 5-Year Change | 0.57% |
| 10-Year Change | 13.29% |
| Growth Volatility | 6.06 |
HYUNDAI BIOLAND Co.Ltd - Net Assets Trend (2011–2024)
This chart illustrates how HYUNDAI BIOLAND Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HYUNDAI BIOLAND Co.Ltd (2011–2024)
The table below shows the annual net assets of HYUNDAI BIOLAND Co.Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩138.01 Billion | +1.49% |
| 2023-12-31 | ₩135.98 Billion | +5.18% |
| 2022-12-31 | ₩129.29 Billion | +3.14% |
| 2021-12-31 | ₩125.35 Billion | -8.66% |
| 2020-12-31 | ₩137.23 Billion | -11.88% |
| 2019-12-31 | ₩155.72 Billion | +4.58% |
| 2018-12-31 | ₩148.91 Billion | +8.05% |
| 2017-12-31 | ₩137.82 Billion | +5.58% |
| 2016-12-31 | ₩130.53 Billion | +7.16% |
| 2015-12-31 | ₩121.82 Billion | +6.41% |
| 2014-12-31 | ₩114.48 Billion | +6.59% |
| 2013-12-31 | ₩107.40 Billion | +6.70% |
| 2012-12-31 | ₩100.65 Billion | +7.89% |
| 2011-12-31 | ₩93.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to HYUNDAI BIOLAND Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11209504402000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩112.10 Billion | 81.22% |
| Common Stock | ₩15.00 Billion | 10.87% |
| Other Components | ₩10.91 Billion | 7.91% |
| Total Equity | ₩138.01 Billion | 100.00% |
HYUNDAI BIOLAND Co.Ltd Competitors by Market Cap
The table below lists competitors of HYUNDAI BIOLAND Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Union Materials Corp
KO:047400
|
$27.07 Million |
|
Foods & Inns Limited
NSE:FOODSIN
|
$27.08 Million |
|
Topview Optronics Corporation
TWO:6556
|
$27.10 Million |
|
Cell MedX Corp
OTCQB:CMXC
|
$27.10 Million |
|
International Gas Product Shipping JSC
VN:GSP
|
$27.03 Million |
|
Development Advance Solution Co Ltd
KO:058730
|
$27.03 Million |
|
GEA Grenobl. Elect.
PA:GEA
|
$27.03 Million |
|
Cytogen Inc
KQ:217330
|
$27.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HYUNDAI BIOLAND Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 135,983,995,950 to 138,008,364,700, a change of 2,024,368,750 (1.5%).
- Net income of 5,703,130,980 contributed positively to equity growth.
- Dividend payments of 1,050,000,000 reduced retained earnings.
- Share repurchases of 64,235,950 reduced equity.
- Other factors decreased equity by 2,564,526,280.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩5.70 Billion | +4.13% |
| Dividends Paid | ₩1.05 Billion | -0.76% |
| Share Repurchases | ₩64.24 Million | -0.05% |
| Other Changes | ₩-2.56 Billion | -1.86% |
| Total Change | ₩- | 1.49% |
Book Value vs Market Value Analysis
This analysis compares HYUNDAI BIOLAND Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.47x to 0.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩8702.14 | ₩4060.00 | x |
| 2017-12-31 | ₩9187.74 | ₩4060.00 | x |
| 2018-12-31 | ₩9927.06 | ₩4060.00 | x |
| 2019-12-31 | ₩10381.57 | ₩4060.00 | x |
| 2020-12-31 | ₩9148.57 | ₩4060.00 | x |
| 2021-12-31 | ₩8356.65 | ₩4060.00 | x |
| 2022-12-31 | ₩8619.11 | ₩4060.00 | x |
| 2023-12-31 | ₩4532.80 | ₩4060.00 | x |
| 2024-12-31 | ₩4600.28 | ₩4060.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HYUNDAI BIOLAND Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.77%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.41x
- Recent ROE (4.13%) is below the historical average (5.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 14.71% | 20.05% | 0.53x | 1.38x | ₩4.39 Billion |
| 2012 | 10.07% | 13.88% | 0.50x | 1.46x | ₩67.20 Million |
| 2013 | 9.06% | 13.70% | 0.50x | 1.33x | ₩-1.01 Billion |
| 2014 | 9.23% | 13.72% | 0.54x | 1.25x | ₩-884.77 Million |
| 2015 | 8.85% | 13.33% | 0.53x | 1.26x | ₩-1.40 Billion |
| 2016 | 9.52% | 12.70% | 0.58x | 1.28x | ₩-626.78 Million |
| 2017 | 8.69% | 11.68% | 0.58x | 1.28x | ₩-1.80 Billion |
| 2018 | 10.11% | 14.96% | 0.52x | 1.30x | ₩156.81 Million |
| 2019 | 6.97% | 10.20% | 0.51x | 1.34x | ₩-4.72 Billion |
| 2020 | -9.87% | -15.24% | 0.47x | 1.37x | ₩-27.27 Billion |
| 2021 | -9.32% | -11.37% | 0.60x | 1.38x | ₩-24.22 Billion |
| 2022 | 3.69% | 4.80% | 0.56x | 1.36x | ₩-8.16 Billion |
| 2023 | 5.92% | 8.33% | 0.53x | 1.35x | ₩-5.54 Billion |
| 2024 | 4.13% | 4.77% | 0.61x | 1.41x | ₩-8.10 Billion |
Industry Comparison
This section compares HYUNDAI BIOLAND Co.Ltd's net assets metrics with peer companies in the Personal & Household Products & Services industry.
Industry Context
- Industry: Personal & Household Products & Services
- Average net assets among peers: $72,208,764,390
- Average return on equity (ROE) among peers: -11.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HYUNDAI BIOLAND Co.Ltd (052260) | ₩137.95 Billion | 14.71% | 0.20x | $27.04 Million |
| Globon Co. Ltd (019660) | $23.23 Billion | 0.00% | 0.16x | $25.19 Million |
| Gentrogroup Co. Ltd. (083660) | $16.51 Billion | -46.25% | 1.01x | $4.07 Million |
| NeoPharm CO. LTD (092730) | $176.88 Billion | 13.04% | 0.09x | $55.87 Million |